Have a feature idea you'd love to see implemented?
Let us know!

- Stocks
- Healthcare
- NASDAQ: DVAX

Price (delayed)

$13.01

Market cap

$1.71B

P/E Ratio

86.73

Dividend/share

N/A

EPS

$0.15

Enterprise value

$1.84B

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of

DVAX's gross margin is up by 24% YoY

Dynavax Technologies's equity has increased by 13% YoY and by 6% from the previous quarter

DVAX's EPS has plunged by 69% YoY but it is up by 15% from the previous quarter

The net income has dropped by 66% year-on-year but it is up by 19% since the previous quarter

DVAX's quick ratio is down by 15% YoY and by 7% QoQ

What are the main financial stats of DVAX

Market
Valuations
Earnings

Shares outstanding

131.45M

Market cap

$1.71B

Enterprise value

$1.84B

Price to earnings (P/E)

86.73

Price to book (P/B)

2.5

Price to sales (P/S)

6.54

EV/EBIT

59.38

EV/EBITDA

47.27

EV/Sales

7.06

Revenue

$260.81M

EBIT

$31.01M

EBITDA

$38.95M

Free cash flow

$22.67M

Per share
Balance sheet
Liquidity

EPS

$0.15

Free cash flow per share

$0.17

Book value per share

$5.2

Revenue per share

$1.99

TBVPS

$8.08

Total assets

$1.06B

Total liabilities

$380.56M

Debt

$250.17M

Equity

$681.43M

Working capital

$856.21M

Debt to equity

0.37

Current ratio

13.23

Quick ratio

11.98

Net debt/EBITDA

3.36

Margins
Efficiency
Dividend

EBITDA margin

14.9%

Gross margin

82.9%

Net margin

7.9%

Operating margin

-4.2%

Return on assets

2%

Return on equity

3.2%

Return on invested capital

2.9%

Return on capital employed

3.1%

Return on sales

11.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Dynavax Technologies stock price performed over time

Intraday

8.24%

1 week

10.44%

1 month

22.39%

1 year

-2.11%

YTD

-6.94%

QTD

16.79%

How have Dynavax Technologies's revenue and profit performed over time

Revenue

$260.81M

Gross profit

$216.09M

Operating income

-$10.98M

Net income

$20.48M

Gross margin

82.9%

Net margin

7.9%

The company's operating margin has shrunk by 144% YoY but it rose by 34% QoQ

DVAX's operating income has dropped by 132% year-on-year but it is up by 31% since the previous quarter

The net income has dropped by 66% year-on-year but it is up by 19% since the previous quarter

Dynavax Technologies's net margin has plunged by 53% YoY but it has increased by 14% from the previous quarter

What is Dynavax Technologies's growth rate over time

What is Dynavax Technologies stock price valuation

P/E

86.73

P/B

2.5

P/S

6.54

EV/EBIT

59.38

EV/EBITDA

47.27

EV/Sales

7.06

DVAX's EPS has plunged by 69% YoY but it is up by 15% from the previous quarter

DVAX's P/B is 76% below its 5-year quarterly average of 10.5

Dynavax Technologies's equity has increased by 13% YoY and by 6% from the previous quarter

DVAX's revenue is down by 28% year-on-year but it is up by 4.5% since the previous quarter

The P/S is 7% less than the 5-year quarterly average of 7.0

How efficient is Dynavax Technologies business performance

The ROE has plunged by 70% YoY but it has grown by 14% from the previous quarter

Dynavax Technologies's ROA has plunged by 68% YoY but it has increased by 18% from the previous quarter

Dynavax Technologies's return on invested capital has shrunk by 61% YoY but it has increased by 21% QoQ

DVAX's ROS is down by 38% YoY but it is up by 18% from the previous quarter

What is DVAX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DVAX.

How did Dynavax Technologies financials performed over time

Dynavax Technologies's total assets is 179% higher than its total liabilities

DVAX's quick ratio is down by 15% YoY and by 7% QoQ

Dynavax Technologies's current ratio has decreased by 14% YoY and by 7% QoQ

Dynavax Technologies's debt is 63% less than its equity

Dynavax Technologies's equity has increased by 13% YoY and by 6% from the previous quarter

The debt to equity has contracted by 12% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.